CNTB Stock News & Catalysts – Connect Biopharma

FEATURED

3 Biotech Stocks Throwing Their Weight Around, and Another that Wants to Help You Lose Yours

DENVER, Sept. 30, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- The biotech market is heading into a stretch of unusually dense catalysts, with regulatory meetings, Phase 2 readouts, potential Phase 3 transitions

Summary

Sep 30, 2026, 10:22 AM ·Globe Newswire

RECENT

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) – – Rademikibart significantly reduced the rate of new moderate to severe COPD exacerbations

Sep 30, 2026, 7:00 AM ·Globe Newswire

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation

– Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo – –Rademikibart produced a rapid, statistically significant improvement in lung function at Day 7 compared to

Sep 15, 2026, 7:00 AM ·Globe Newswire

Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for

Sep 3, 2026, 4:05 PM ·Globe Newswire

Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update

– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – – Cash runway

Aug 12, 2026, 4:05 PM ·Globe Newswire

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet with cash runway

Jun 17, 2026, 9:00 AM ·Globe Newswire

Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the

May 12, 2026, 4:05 PM ·Globe Newswire

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis – – Expect to report topline data from both Phase 2

May 12, 2026, 9:00 AM ·Globe Newswire

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for

Apr 23, 2026, 9:00 AM ·Globe Newswire

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – – Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-breaking research session

Mar 31, 2026, 4:05 PM ·Globe Newswire

Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients – – Rademikibart was well tolerated with safety comparable to

Mar 30, 2026, 7:01 AM ·Globe Newswire

Connect Biopharma Announces $20.2 Million Private Placement Financing

Funding from new and existing investors extends anticipated cash runway into the second half of 2027 SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect

Mar 30, 2026, 7:02 AM ·Globe Newswire

Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD

– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV1 with many patients experiencing improvements in

Mar 30, 2026, 7:00 AM ·Globe Newswire

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for

Mar 10, 2026, 9:00 AM ·Globe Newswire

Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference

SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma", "Connect", or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care

Mar 3, 2026, 9:00 AM ·Globe Newswire

Connect Biopharma Holdings Limited CNTB · News